Biotech Essentials

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 15.12.2020.

Initial public offering
Google
Venture capital
Vice President of the United States
Bristol-Myers Squibb
Boston Red Sox

Startups

@Forbes shared
On Dec 12, 2020
Meet the Fiskers, the billionaire power couple taking on Tesla: https://t.co/s1YMZ0bw8d https://t.co/LYwCXUJBhI
Open
Meet The Fiskers, The Billionaire Power Couple Taking On Tesla

Meet The Fiskers, The Billionaire Power Couple Taking On Tesla

Famed car designer Henrik Fisker is mounting a comeback seven years after his pioneering electric vehicle company collapsed.

@BiotechWorld shared
On Dec 10, 2020
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race https://t.co/v45rtyHW9c https://t.co/Z6q4J2tcqG
Open
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race

Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race

Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate (ADC) to its pipeline. The deal comes one month ...

@big4bio shared
On Dec 14, 2020
RT @BobCoughlin: After more than 13 years leading @MassBio, today I am announcing that I will be stepping down as President & CEO of this wonderful organization in early 2021. Read my letter to the MassBio community: https://t.co/xkhachL0SB
Open
“I’m Moving On. MassBio is Set-Up for Success.” A Note from Robert K. Coughlin

“I’m Moving On. MassBio is Set-Up for Success.” A Note from Robert K. Coughlin

Dear MassBio Community, After more than 13 years leading this wonderful organization, today I am announcing that I will be stepping down as President & CEO of MassBio in early 2021. ...

@matthewherper shared
On Dec 8, 2020
RT @adamfeuerstein: STAT is typically private about financial performance, readership metrics, but ocassionally, you have to open up. I’m incredibly proud to be a part of @statnews sucess story. It’s a credit to our ownership, leadership and every one of my colleagues. https://t.co/qrmLPOtQot
Open
Exclusive: STAT News plans major expansion following banner year

Exclusive: STAT News plans major expansion following banner year

"Covid didn't save us, but it helped propel us a lot faster."

@ReutersBiz shared
On Dec 14, 2020
Biotech, pharma investments on VC radar in 2021 - PitchBook https://t.co/VaCyqDfL7e https://t.co/05MCecSelS
Open
Biotech, pharma investments on VC radar in 2021 - PitchBook

Biotech, pharma investments on VC radar in 2021 - PitchBook

The two main areas for venture capitalist (VC) investment - technology and healthcare - have grown during the COVID-19 pandemic and investors have ample dry powder to direct money at ...

@ReutersBiz shared
On Dec 10, 2020
On @Breakingviews: First-day gains in Hong Kong's debuts have bested New York’s this year for only the second time in a decade. JD Health’s 56% jump suggests a more dynamic market following a slew of tech listings, writes @JennHughes13 https://t.co/tHJLjCfX8r https://t.co/Z9MD1GJuVq
Open
Breakingviews - Hong Kong joins the IPO pop parade

Breakingviews - Hong Kong joins the IPO pop parade

Bankers have for years told investors and corporate clients not to expect big first-day gains in Hong Kong like those New York is renowned for. This is no longer true after a series of ...

@JohnCendpts shared
On Dec 12, 2020
AbCellera CEO Carl Hansen earned $115K his last year as a professor at UBC. After the stock shot up 194% on its opening trading day Friday, his 61 million shares are worth $3.6 billion. https://t.co/863ITDp2zw.
Open
Ex-UBC prof Carl Hansen now worth more than $4 billion following spectacular AbCellera Biologics IPO

Ex-UBC prof Carl Hansen now worth more than $4 billion following spectacular AbCellera Biologics IPO

Dec 11, 2020 - His company has identified 500 antibody sequences to SARS-CoV-2, the virus that causes COVID-19.

@BentheFidler shared
On Dec 11, 2020
Lilly's coronavirus drug partner nails down one of #biotech's largest #IPOs https://t.co/UV5fMOQL4E by @realJacobBell $ABCL AbCellera's IPO is biotech's fourth-biggest since 2018 - see where it stacks up here: https://t.co/3oevWN9pls
Open
Lilly's coronavirus drug partner nails down one of biotech's largest IPOs

Lilly's coronavirus drug partner nails down one of biotech's largest IPOs

AbCellera Biologics, a developer of antibody drugs, has raised $483 million through one of the biggest initial public offerings for a biotech in recent years.

Read more: Startups
weekly 15.12.2020
View archives
Back to home